Neuracle Technology (Shanghai) is racing to the Shanghai Stock Exchange’s STAR Market, aiming to secure its legacy as the world’s first publicly traded brain-computer interface (BCI) company. The move comes less than three months after the firm secured the world’s first regulatory certificate for an invasive BCI medical device, the NEO-ONE SCI. While the news has ignited the imaginations of capital markets hungry for a Chinese answer to Elon Musk’s Neuralink, a closer look at the company’s prospectus reveals a stark disconnect between high-concept ambition and financial reality.
Despite the prestige of its recent regulatory win, Neuracle’s invasive BCI technology—designed to help paralyzed patients regain hand function through motor intent recognition—has yet to generate a single yuan in revenue. The NEO-ONE SCI remains in a nascent clinical stage, having been tested on a tiny cohort of just 32 subjects. The path from a niche medical device to a commercial powerhouse is obstructed by significant hurdles, including unknown terminal pricing, a lack of health insurance coverage, and the absence of a proven surgical scaling model.
In the interim, Neuracle’s survival is anchored by a decidedly more traditional business: the sale of non-invasive electroencephalogram (EEG) machines. Between 2023 and 2025, these devices, sold primarily to hospitals and research labs, accounted for over 70% of the firm’s revenue. While Neuracle has achieved a dominant market position in domestic EEG shipments, the business model is showing signs of a plateau. Average unit prices are fluctuating downward, and profit margins, while high, have little room for further expansion.
The company’s financials reflect the heavy toll of deep-tech research and development. Over the past three years, Neuracle has posted a cumulative loss of approximately 328 million RMB ($45 million). While revenue finally crossed the 100 million RMB threshold in 2025, the widening net losses—partially driven by aggressive equity incentives—underscore the reality of a company in a persistent 'cash-burn' phase. For investors, the IPO represents a gamble on a future that remains a decade away, with industry experts generally placing the commercial tipping point for invasive BCI in the 2030s.
Neuracle is not alone in this race, as competitors like BrainCo and several domestic well-funded startups vie for dominance. However, Neuracle's decision to go public now suggests a strategic need to capitalize on 'first-mover' sentiment before the market’s patience for speculative science wears thin. The challenge for the firm will be managing the expectations of a public market that may not have the stomach for the long, arduous road of clinical validation and surgeon training required to turn a laboratory miracle into a mainstream medical reality.